MedTrace Logo

Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

NCT04389541 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 499

Last updated 2023-08-14

No results posted yet for this study

Summary

The retrospective cohort study INFINITY will be an instrument to analyze the current practice of precision oncology in the real-world setting. It will provide insight into real-world biomarker-directed treatment of cancer patients not eligible for standard therapies. The study will retrospectively collect medical records' data of patients who received a targeted treatment based on a potentially actionable alteration or biomarker identified by molecular diagnostics. Data of deceased patients will be included. The study will analyze how molecular test results guided clinical decision making. The compiled treatment and outcome data will be a valuable resource to analyze the use and effectiveness of targeted therapy approaches in biomarker-defined and entity-defined subpopulations of cancer patients. These signals might generate new insights and foster progress of targeted cancer treatment. The associated biomarker profiling module aims to set up a decentral biobank for future research on molecular alterations or central re-testing.

Conditions

  • Advanced Solid Tumors or Hematologic Malignancies

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Roche Pharma AG

    collaborator INDUSTRY

  • iOMEDICO AG

    lead INDUSTRY

Principal Investigators

  • Norbert Marschner, MD · Outpatient center for hematology and oncology, Freiburg, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-17
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04389541 on ClinicalTrials.gov